Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Value-based care sounds simple—until you open Agilon Health’s latest 300-page filing and wade into risk-share tables, capitated revenue, and CMS adjustment formulas. If parsing those details feels daunting, you’re not alone.
Stock Titan turns that complexity into clarity. Our AI instantly translates every Agilon Health annual report 10-K simplified, flags shifts in medical-cost ratios inside each Agilon Health quarterly earnings report 10-Q filing, and alerts you the moment an Agilon Health 8-K material events explained hits EDGAR. Want to monitor physician-executive incentives? Real-time dashboards surface Agilon Health insider trading Form 4 transactions and send push alerts for any Agilon Health Form 4 insider transactions real-time.
Here’s what you can explore on this page:
- 10-K and 10-Q drill-downs that reveal how Agilon funds new physician groups and measures quality bonuses—understanding Agilon Health SEC documents with AI.
- Instant text and chart summaries that connect risk-adjustment revenue in 8-Ks to quarterly guidance—comprehensive Agilon Health earnings report filing analysis.
- Form 4 feeds outlining option grants and stock sales, perfect for tracking Agilon Health executive stock transactions Form 4.
- Proxy excerpts breaking down CEO compensation and partnership incentive pools—your shortcut to the latest Agilon Health proxy statement executive compensation.
Whether you’re a portfolio manager benchmarking medical-cost trend, an analyst searching for segment profitability, or a physician-investor curious about partner economics, our AI-powered summaries, expert context, and real-time updates give you the answers faster than ever. No more scrolling—just the insights that matter.
North Peak disclosed a passive stake in agilon health totaling 21,536,679 shares, representing 5.2% of outstanding common stock based on 414,423,149 shares.
The filing is a joint Schedule 13G dated 08/22/2025 showing ownership across related entities: North Peak Capital Partners, LP (1,247,465 shares), North Peak Capital Partners II, LP (10,585,833 shares), North Peak Capital Alpha Fund, LP (5,564,235 shares) and North Peak Capital Ultra Fund, LP (878,841 shares). Certain affiliates and principals (North Peak Capital Management, North Peak GP, and Jeremy and Michael Kahan) report shared voting or dispositive power over 18,276,374 shares (4.4%).
The statement clarifies the holdings are reported as passive (Schedule 13G) and includes a joint filing agreement; it does not state any intent to influence control of the issuer.
Form 4 filed for agilon health, inc. (AGL) reports a transaction by Timothy Gertsch, identified as an officer (Chief Accounting Officer) and director. The filing records a transaction dated 08/16/2025 coded "F" showing "406(1) D" at a price of $1.11 and reports 114,752 shares beneficially owned following the reported transaction. The form's explanation states that the "406" figure represents shares withheld by the issuer to satisfy income tax withholding in connection with net settlement of restricted stock units and that this withholding "does not represent a sale." The form is signed by an attorney-in-fact on 08/19/2025.
Capital World Investors reports a material stake in agilon health. The filing discloses beneficial ownership of 45,570,601 shares of agilon health common stock, equal to 11.0% of the 413,951,779 shares believed outstanding. The filer reports sole voting and sole dispositive power over all reported shares.
The disclosure identifies Capital World Investors as a division of Capital Research and Management Company together with its investment management subsidiaries and affiliates that collectively provide investment services under the Capital World Investors name. The statement affirms the securities are held in the ordinary course of business and are not held to change or influence control of the issuer. Item 6 lists American Funds Fundamental Investors in the context of ownership on behalf of another person.
Capital International Investors reported beneficial ownership of 9,892,742 shares of agilon health common stock, equal to 2.4% of 413,951,779 shares outstanding. CII is presented as a division of Capital Research and Management Company and affiliated investment management entities and states it has sole voting and sole dispositive power over those 9,892,742 shares with no shared power. The disclosure is filed on a Schedule 13G/A as an IA (investment adviser) and the filing notes this is an ownership position of 5% or less. The signer certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FMR LLC (Fidelity) and Chair & CEO Abigail P. Johnson filed a Schedule 13G reporting a passive 9.4 % stake in agilon health, Inc. (AGL) as of 30 Jun 2025. The group beneficially owns 38,760,723 common shares, with FMR holding sole voting power over 38,742,056 shares and sole dispositive power over the full position; no shared voting or dispositive rights were disclosed. The filing was made under Rule 13d-1(b) for a parent holding company/control person, indicating the shares were acquired in the ordinary course of business and not to influence control of the issuer. No other individual investor within the Fidelity complex owns more than 5 % of AGL. The declaration, signed 5 Aug 2025 by attorney-in-fact Richard Bourgelas, certifies passive intent. While the disclosure does not signal corporate action, it materially raises AGL’s institutional ownership base and may enhance liquidity and market visibility.
agilon health (AGL) filed an 8-K covering multiple governance and disclosure items. On 29 Jul 2025 Chief Executive Officer & President Steven J. Sell resigned, classified as a termination without “cause.” He will receive contractual severance; details reference the 2025 proxy. The Board size falls to seven and an “Office of the Chairman” is established, led by Executive Chairman Ron Williams and six other senior officers; CFO Jeffrey Schwaneke and Chief Markets Officer Benjamin Shaker become interim principal executive officers.
Concurrently, the Board amended and restated the company by-laws to redefine certain officer roles and incorporate technical Delaware law updates (filed as Ex. 3.1). Under Items 2.02 and 7.01 the company furnished—but did not file—press releases and an investor presentation (Exs. 99.1-99.3) containing Q2 2025 results and leadership changes; specific financial metrics are not included in this filing.
No related-party transactions were disclosed beyond existing indemnification agreements. Overall, the filing highlights a sudden CEO departure, interim leadership measures, and administrative charter updates.